<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569465</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT 2004-004203-38</org_study_id>
    <nct_id>NCT00569465</nct_id>
  </id_info>
  <brief_title>N-Acetylcysteine and Arginine Administration in Diabetic Patients</brief_title>
  <acronym>NACARGPAO</acronym>
  <official_title>Effects of Arginine and N-Acetylcysteine Administration on Nitric Oxide Production and Arterial Blood Pressure in Hypertensive Diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been demonstrated that the nitric oxide production is reduced in type 2 diabetic&#xD;
      patients and that cardiovascular complications represent 80% of the causes of death in these&#xD;
      patients. As nitric oxide is able to reduce platelet aggregation, increase the relaxation of&#xD;
      smooth muscle cells, and reduce plasminogen activator inhibitor-1 and endothelin, we&#xD;
      hypothesized that nitric oxide deficiency is responsable for the cardiovascular disease in&#xD;
      type 2 diabetes mellitus. Arginine and N-acetylcysteine, precursor and enhancer of the nitric&#xD;
      oxide synthesis respectively, are able to increase nitric oxide production.&#xD;
&#xD;
      Aim of the study is to evaluate the effect of arginine and N-acetylcysteine administration on&#xD;
      arterial blood pressure and different metabolic parameters in patients with type 2 diabetes&#xD;
      mellitus and hypertension.&#xD;
&#xD;
      Subjects and methods. 24 male subjects, randomly divided in two groups, will be studied.&#xD;
      These subjects will undergo a treatment with arginine (1200 mg once a day) plus&#xD;
      N-acetylcysteine (600 mg twice a day) or placebo for six months. Basal and final evaluations&#xD;
      include:&#xD;
&#xD;
        -  general examination&#xD;
&#xD;
        -  ABPM (ambulatory blood pressure monitoring)&#xD;
&#xD;
        -  HbA1c, total-cholesterol, HDL-cholesterol, LDL-cholesterol, oxidized LDLs,&#xD;
           triglycerides, reduced/oxidized glutathione ratio in red blood cells, nitrites/nitrates,&#xD;
           asymmetrical and symmetrical dimethyl-arginine, nitrotyrosine, arginine, homocysteine,&#xD;
           C-reactive protein, interleukin-6, tumor necrosis factor-Î±, intercellular and&#xD;
           vascular-cell adhesion molecules, plasminogen activator inhibitor-1 and fibrinogen&#xD;
&#xD;
        -  the ultrasound assessment of the intima-media thickness after endothelium-dependent&#xD;
           flow-mediated vasodilation of the brachial artery&#xD;
&#xD;
      Expected results. Increase of nitric oxide production and reduction of arterial blood&#xD;
      pressure and oxidative parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    End of the study&#xD;
  </why_stopped>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>arterial blood pressure decrease</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxidative parameters decrease</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine</intervention_name>
    <description>1200 mg, once a day</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Zentrum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcysteine</intervention_name>
    <description>600 mg twice a day</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Acetilcisteina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 vials a day</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects&#xD;
&#xD;
          -  Age between 40 and 70 years&#xD;
&#xD;
          -  Type 2 diabetes mellitus and hypertension&#xD;
&#xD;
          -  Mean 24h arterial blood pressure after the wash-out period: systolic &gt;136mmHg and/or&#xD;
             diastolic &gt;86 mmHh&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects&#xD;
&#xD;
          -  Mean 24h arterial blood pressure after the wash-out period: systolic &gt;180 mmHg and/or&#xD;
             diastolic &gt;110 mmHg&#xD;
&#xD;
          -  Secondary hypertension&#xD;
&#xD;
          -  Significative cardiovascular complications of diabetes&#xD;
&#xD;
          -  Cancer or severe systemic, hepatic, pulmonary, cardiovascular or diseases&#xD;
&#xD;
          -  Actual treatment with nitrates, acetylcysteine or arginine&#xD;
&#xD;
          -  Acetylcysteine hypersensitivity&#xD;
&#xD;
          -  Psychiatric disturbs, abuse of drugs or alcohol&#xD;
&#xD;
          -  Low compliance&#xD;
&#xD;
          -  Absence of written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentino Martina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>&quot;San Giovanni Battista&quot; Hospital of Turin</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <last_update_submitted>December 6, 2007</last_update_submitted>
  <last_update_submitted_qc>December 6, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2007</last_update_posted>
  <responsible_party>
    <name_title>Prof. Valentino Martina</name_title>
    <organization>University of Turin</organization>
  </responsible_party>
  <keyword>nitric oxide</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>diabetes</keyword>
  <keyword>hypertension</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

